Mersana Therapeutics to Present at Upcoming Investor Conferences
Mersana Therapeutics, Inc. (NASDAQ: MRSN) has announced management presentations at two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mersana Therapeutics, Inc. (NASDAQ: MRSN) has announced management presentations at two upcoming investor conferences. The first is the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 4:15 p.m. ET, followed by the Baird 2022 Global Healthcare Conference on September 13, 2022, at 2:00 p.m. ET. A live webcast of the Morgan Stanley event will be available on Mersana's website, with a replay accessible for 90 days. Mersana focuses on developing antibody-drug conjugates (ADCs) for cancer treatment, notably its lead candidate, UpRi.
Details
News Market Reaction – MRSN
The recorded move for MRSN in the trading session of this news was -2.58%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at two upcoming investor conferences. Details are as follows:
| Morgan Stanley 20th Annual Global Healthcare Conference | |
| Format: | Fireside Chat |
| Date/Time: | Monday, September 12, 2022, at 4:15 p.m. Eastern Time |
| Baird 2022 Global Healthcare Conference | |
| Format: | Fireside Chat |
| Date/Time: | Tuesday, September 13, 2022, at 2:00 p.m. Eastern Time |
A live webcast of the fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the event.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana Therapeutics was named among the 2021 Top Places to Work in Massachusetts by The Boston Globe. Mersana routinely posts information that may be useful to investors on the “Investors and Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.